• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Peptides mimicking cardiac receptors combat autoimmune-mediated heart failure [PreClinical]

byJudith KandelandSarah Stapleton
February 27, 2015
in Cardiology, Chronic Disease, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In an animal model of autoimmune-mediated heart failure (HF), prophylactic or therapeutic treatment with a cyclopeptide mimicking a cardiac receptor dramatically blocked or reverted disease progression.

2. Continued treatment with the cyclopeptide permanently lowered antibodies associated with HF through both scavenger methods as well as targeted depletion of antibody-producing B cells.

Evidence Rating Level: 3 (Average)

Study Rundown: Causes of HF are diverse in origin, with one being the autoimmune production of antibodies targeting the second extracellular loop of the cardiac β1 adrenergic receptor (anti-EC2β1). It is thought that these antibodies lead to continuous stimulation of the β1 adrenergic receptor (β1AR), ultimately leading to HF. Rather than using beta blockers, such as bisoprolol, against β1AR to treat this type of HF, the authors here developed EC2-CP, a cyclopeptide that mimics the EC2β1 region of β1AR and thus prevents anti-EC2β1 from binding cell-derived β1AR. A cyclic, rather than linear (EC2-lin), version of the peptide was used because of its superior stability and increased recognition by anti-EC2β1.

Animal studies involved injecting rats with EC2β1 to stimulate anti-EC2β1 production, with boosters administered monthly afterwards. EC2-CP injection every 4 weeks, alone or combined with bisoprolol, was able to prevent (treatment initiated soon after anti-EC2β1 stimulation) or reverse (treatment initiated 8.5 months after anti-EC2β1 stimulation) cardiac damage. This was demonstrated by cardiac output parameters, histological analyses, and quantification of protein and gene expression. Interestingly, titer levels of anti-EC2β1 were permanently reduced by EC2-CP treatment in both studies, an effect not seen with bisoprolol treatment. Further studies revealed profoundly decreased levels of splenic EC2β1 targeting memory B cells in the EC2-CP treatment groups, representing a second way by which EC2-CP targets anti-EC2β1.

HF in the clinical setting is often the result of a complex web of contributing factors, so further studies reflecting this reality are needed before this approach can be applied clinically. Should clinical trials corroborate these animal results, this work presents a possible treatment plan catered towards patients with autoimmune HF by targeting anti-EC2β1.

Click to read the study in PLOS ONE

RELATED REPORTS

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

Dapagliflozin efficacious and safe in treating heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

Relevant Reading: Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy

In-Depth [animal study]: A total of 114 rats were used in this study. Enzyme linked immunosorbent assay (ELISA) was used to show superior affinity of anti-EC2β1 in blood to EC2-CP than to EC2-lin (p<0.005). Ex vivo stability studies gave the EC2-CP half-life as 486 hours, while EC2-lin had a 4 hour half-life. β1AR activation induced by anti-EC2β1, as measured by cyclic adenosine monophosphase (cAMP) signaling, was also more greatly decreased with EC2-CP than by EC2-lin.

EC2-CP, other peptides or bisoprolol were administered every 4 weeks beginning 6 weeks or 8.5 months after EC2β1 injection for prevention or treatment studies, respectively. In both studies, 5 injections of EC2-CP reduced anti-EC2β1 titers by 80-90%. Animals immunized but not treated showed increased left ventricular diameter and lowered ejection fractions and cardiac indices (p<0.001 by 12 months for all parameters), among other cardiac function measurements. EC2-CP treatment reversed this trend in both study groups when given alone (preventive or treatment) or with bisoprolol (treatment). Cardiac scarring (p<0.05) and apoptosis (p<0.001) induced by EC2β1 immunization was also returned to control levels by EC2-CP treatment. Importantly, bisoprolol treatment did decrease the effects of EC2β1 immunization on all of the parameters, but to a lesser degree than EC2-CP treatment.

Finally, the authors were interested in further elucidating the permanent decrease in titer levels induced by EC2-CP treatment. They found that while the number of IgG producing splenocytes were equivalent in untreated and EC2-CP treated immunized rats, EC2-CP treatment decreased the fraction of cells specific to EC2β1 (p<0.05, n=2-3 rats). This result was further supported by flow cytometry experiments.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: heart failure
Previous Post

The HAPO trial: hyperglycemia and adverse pregnancy outcomes [Classics Series]

Next Post

Active smoking may increase mortality among colorectal cancer survivors

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

June 9, 2022
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Next Post
Flexible sigmoidoscopy decreases colorectal cancer incidence and mortality

Active smoking may increase mortality among colorectal cancer survivors

Hypothyroidism prevalence correlated with fluoride in drinking water

Hypothyroidism prevalence correlated with fluoride in drinking water

Family planning providers use long acting contraception more than general population

Family planning providers use long acting contraception more than general population

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.